James Bussel
Pediatric Hematology-Oncology · New York, NYNPI 1063509156
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $153,471 of the $203,737 with a category attached, or 75.3%. It is spread thinly across 18 manufacturers, the largest accounting for just 18.8%. Reporting peaked in 2019 at $56,841 and has fallen 96.0% since, to $2,264 in 2025. Among pediatric hematology-oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $1520.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dova Pharmaceuticals$38K
- Novartis$25K
- Sobi, Inc$23K
- Amgen$16K
- UCB SA$15K
- Novartis Pharma AG$15K
- plus $72K from 12 others
Across 42 payments — averaging $1491.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$47K
- Amgen$13K
- Octapharma USA, Inc.$1K
- Janssen Global Services, LLC$600
- UCB, Inc.$420
What the payments were for
- Consulting fees$153,47175%
- Speaking & faculty fees$26,36713%
- Travel & lodging$21,29310%
- Food & beverage$2,6061%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dova Pharmaceuticals | 16 | $38,382 |
| Novartis | 17 | $24,947 |
| Sobi, Inc | 14 | $23,062 |
| Amgen | 13 | $15,764 |
| UCB SA | 8 | $14,980 |
| Novartis Pharma AG | 6 | $14,590 |
| Sanofi | 9 | $11,129 |
| Janssen Research & Development, LLC | 7 | $10,550 |
| Grifols USA, LLC | 5 | $9,349 |
| CSL Behring | 3 | $7,880 |
| Rigel Pharmaceuticals, Inc. | 15 | $7,263 |
| Argenx US, Inc. | 12 | $6,554 |
| Grifols Shared Services North America, Inc. | 3 | $5,036 |
| Regeneron | 1 | $4,583 |
| Astrazeneca UK Limited | 2 | $4,110 |
| AstraZeneca | 1 | $3,083 |
| Swedish Orphan Biovitrum AB | 1 | $2,420 |
| Incyte Corporation | 1 | $57 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$203,737 in reported general payments places this provider in the 95th percentile of 196 pediatric hematology-oncology providers in New York.
See all pediatric hematology-oncology providers in New York →
Other pediatric hematology-oncology in New York
- Sujit ShethNew York$359K
- Jaap Jan BoelensNew York$303K
- Saara KavianyNew York$144K
- Gary BrittenhamNew York$137K
- James FerraraNew York$118K
- John LevineNew York$98K
- Nai-Kong CheungNew York$86K
- Andrew HarrisNew York$85K
- Joseph OvedNew York$77K
- Catherine McGuinnNew York$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.